| Stereochemistry | ACHIRAL |
| Molecular Formula | C6H17NO7P2 |
| Molecular Weight | 277.1492 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O
InChI
InChIKey=PUUSSSIBPPTKTP-UHFFFAOYSA-N
InChI=1S/C6H17NO7P2/c7-5-3-1-2-4-6(8,15(9,10)11)16(12,13)14/h8H,1-5,7H2,(H2,9,10,11)(H2,12,13,14)
Neridronic acid (6-amino-1-idroxyesilidene-1,1-bisphosphonate) is a nitrogen-containing bisphosphonate licensed in Italy for the treatment of osteogenesis imperfecta and Paget’s disease of bone. The pharmacodynamic profile is similar to that of other nitrogen-containing bisphosphonates and is characterized by its high affinity for bone tissue particularly at sites undergoing a process of remodeling. In growing children affected by osteogenesis imperfect, neridronic acid rapidly increases bone mineral density as measured by dual X-ray absorptiometry and this is associated with a significant decrease in fracture cumulative number. Similar results have been obtained also in newborns (<12-month-old) and in adult patients. In Paget’s disease of bone, 200 mg intravenous neridronic acid is associated with a 65% rate of full remission and a biochemical response (decrease of > 75% of bone turnover markers) in 95% of the patients. Neridronic acid treatment has been reported to be effective also in other skeletal diseases such as osteoporosis, algodystrophy, hypercalcemia of malignancy and bone metastasis. Neridronic acid has been developed only for parenteral use, and it is the only one used as the intramuscular injection. This avoids all the limitations of oral bisphosphonates and may be offered for a home treatment with simple nursing assistants
Originator
Approval Year
Doses
PubMed
Patents
Sample Use Guides
Neridronic acid is licensed in Italy for the treatment of Paget’s disease at the dose of 100 mg dissolved in 250 ml of saline solution given i.v. for 2 consecutive days.
Neridronic acid 25 mg i.m. monthly is also effective in fully preventing the changes in bone turnover markers and BMD associated with androgen deprivation therapy for prostatic cancer
Route of Administration:
Other
MDA-MB-231, U87-MG and Caco2 cells were used for activity evaluation. Cells were seeded at a density of 10^4 cells per well in 96-well flat-bottom plates (Falcon, Strasbourg, France) and incubated in completed culture medium for 24 h. Then, medium was removed and replaced by 10% FCS-medium containing increasing concentrations of neridronate from 16 nkM to 1 mM and varying concentration of liposomal suspension containing neridronate from 0.27 mkM to 17.56 mkM. After 72 h incubation (free neridronate) or 24 h, 48 h and 72 h incubation (liposomal neridronate), cells were washed with phosphate buffered saline (PBS, Life Technologies) and incubated with 0.1 ml of MTT (2 mg/ml, Sigma–Aldrich) for additional 4 h at 37 C. The insoluble product was then dissolved by addition of 100 mkl of DMSO (Sigma–Aldrich). The absorbance corresponding to the solubilized formazan pellet (which reflects the relative viable cell number) was measured at 570 nm using a Labsystems Multiskan MS microplate reader. Dose–response curves were obtained for free and liposomal neridronate concentrations, allowing the determination of EC50 values, which refer to the concentration inducing a response halfway between the baseline and the maximum plateau reached.
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
